We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » AbbVie’s Rinvoq gets Green Light in EU for Severe Atopic Dermatitis
AbbVie’s Rinvoq gets Green Light in EU for Severe Atopic Dermatitis
AbbVie’s Rinvoq has gotten the thumbs up from the European Commission (EC) for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 and older who are candidates for systemic therapy, becoming the first Janus kinase (JAK) inhibitor approved for the condition in the EU for both adults and adolescents.